Evidence map›Paper›PMID 39441620›Full record

ArticleActa crystallographica. Section F, Structural biology communications2024

Human transforming growth factor β type I receptor in complex with kinase inhibitor SB505124.

Jhon A Rodriguez Buitrago, Maréne Landström, Magnus Wolf-Watz

Abstract read
In one paragraph

Article in Acta crystallographica. Section F, Structural biology communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jhon A Rodriguez BuitragoDepartment of Chemistry, Umeå University, Linnaeus vag 10, 901 87 Umeå, Sweden.ORCID 0000-0003-1693-3916
Maréne LandströmDepartment of Medical Biosciences, Umeå University, 901 85 Umeå, Sweden.ORCID 0000-0001-6737-7230
Magnus Wolf-WatzDepartment of Medical Biosciences, Umeå University, 901 85 Umeå, Sweden.ORCID 0000-0002-9098-7974

Funding

Cancerfonden 23 2902 Pj 01HUmeå Universitet FS 506-21Vetenskapsrådet 2021-04513_VRVetenskapsrådet 2023-02370_VR
6 · The paper itself

Abstract

The crystal structure of the intracellular domain of transforming growth factor β type I receptor (TβR1) in complex with the competitive inhibitor SB505124 is presented. The study provides insights into the structure and function of TβR1 in complex with SB505124, and as such offers molecular-level understanding of the inhibition of this critical signalling pathway. The potential of SB505124 as an avenue for therapy in cancer treatment is discussed on basis of the results.

Indexed as

Protein Kinase InhibitorsReceptor, Transforming Growth Factor-beta Type IBinding SitesCrystallography, X-RayHumansModels, MolecularProtein BindingProtein Serine-Threonine KinasesReceptors, Transforming Growth Factor betaProtein Kinase InhibitorsProtein Serine-Threonine KinasesReceptors, Transforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type ITGFBR1 protein, humaninhibitionintracellular domainosteoblast differentiationprostate cancerTGF-β type I receptor

Identifiers

PMID39441620
PMCPMC11533363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.